Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-668 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Participants grouped in different cohorts will receive a single ascending dose of VX-668. |
| Placebo Part A | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-668. |
| Part B | EXPERIMENTAL | Participants grouped in different cohorts will receive multiple doses of VX-668.The dose levels will be determined based on the data from Part A. |
| Placebo Part B | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-668. |
| Name | Type | Description |
|---|---|---|
| VX-668 | DRUG | Suspension for oral administration. |
| Placebo | DRUG | Suspension for oral administration. |
Key Inclusion Criteria: * Participants of age between 18 to 55 years (inclusive) * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * A total body weight of more than (\>)50 kg * Nonsmoker or ex-smoker for at least 3 months before screening Key Exclusion Criteria: * Any c...
VX-668 is an investigational small molecule being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare genetic condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
VX-668 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical research on this investigational drug for Alpha-1 Antitrypsin Deficiency.
VX-668 is in Phase 1 clinical development. A first-in-human study of the drug has been completed, and it remains an investigational agent that has not received regulatory approval for any use.
VX-668 has one completed Phase 1 clinical trial registered as NCT05727800. This first-in-human study enrolled 114 participants in the United States, included healthy volunteers, and was randomized, double-blind, and placebo-controlled.
VX-668 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Alpha-1 Antitrypsin Deficiency. The completed Phase 1 trial was a first-in-human study, and the drug has not yet progressed to later-stage trials or regulatory review.